Advaxis to Webcast Investor & Analyst Day 2017
June 09 2017 - 8:00AM
Business Wire
Focus on Patients, Partnerships and
Progress
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company
developing cancer immunotherapies, today announced that its annual
Investor & Analyst Day, scheduled for Monday, June 12, 2017 at
1:00 p.m., will be webcast live.
To access the live webcast, remote individuals can visit
www.event.webcasts.com. Full contact information and company
affiliation are required to access the webcast. For those
interested in attending in-person in New York City, please register
online. The presentation program and agenda is now available at the
same link, and full presentation slides and audio will be available
for viewing on Tuesday, June 13.
At the event, presentations will focus on Patients, Partnerships
and Progress, providing updates on the company’s Lm Technology™ and
nine development programs. Clinical investigators sharing their
experiences and case studies during this year’s event include:
- Sharad Ghamande, MD, an associate
professor and Director of Gynecologic Oncology at the Georgia
Cancer Center at Augusta University, who is a principal
investigator in Advaxis’ Phase 1 study of axalimogene filolisbac
evaluated at higher doses in women with metastatic cervical
cancer.
- Cathy Eng, MD, FACP, who is a professor
and the Associate Medical Director, Colorectal Center, Division of
Cancer Medicine at the University of Texas MD Anderson Cancer
Center. Dr. Eng is the principal investigator in Advaxis’ Phase 2
FAWCETT study, evaluating axalimogene filolisbac in patients with
metastatic anal cancer.
- Nicola Mason, PhD, BVetMed, an
associate professor of medicine and pathobiology at the University
of Pennsylvania School of Veterinary Medicine, specializing in
canine cancer, is an investigator evaluating ADXS-HER2 in dogs with
surgically treated osteosarcoma.
- Brian Slomovitz, MD, who is the
Director of the Division of Gynecologic Oncology in the Department
of Obstetrics and Gynecology at the University of Miami Miller
School of Medicine, as well as Co-leader of the Gynecologic Cancers
Site Disease Group at Sylvester Comprehensive Cancer Center. Dr.
Slomovitz is a co-principal investigator on the company’s Phase 3
AIM2CERV trial in high-risk, locally advanced cervical cancer and
an investigator evaluating axalimogene filolisbac in combination
with AstraZeneca’s durvalumab in metastatic cervical cancer.
- Mark Stein, MD, a medical oncologist at
the Rutgers Cancer Institute of New Jersey, working across multiple
disciplines in the Prostate Cancer Program and the Urologic
Oncology Program, is an investigator in a Phase 1/2 trial
evaluating ADXS-PSA in patients with previously treated, metastatic
castration-resistant prostate cancer (mCRPC).
Advaxis senior management will also share details on the
company’s clinical development, the collaboration with Amgen, Inc.
on ADXS-NEO and plans for regulatory submission and
commercialization. Advaxis presentations include:
- Robert Petit, PhD, discussing
axalimogene filolisbac and a potential prognostic biomarker, and
preclinical work with Lm-WT1, ADXS-NEO and ADXS-HOT
- Mayo Pujols, discussing details of the
IND for ADXS-NEO
- Fatima Ahmad, PharmD, sharing a
publication and congress overview
- Bob Ashworth, PhD, providing a EU
regulatory approval update
- Chris Duke presenting Advaxis’ plan for
EU commercial readiness
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a late-stage
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology. Lm Technology,
using bioengineered live attenuated Listeria
monocytogenes (Lm) bacteria, is the only known cancer
immunotherapy agent shown in preclinical studies to both generate
cancer fighting T cells directed against cancer antigens and
neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that
protect the tumor microenvironment from immunologic attack and
contribute to tumor growth. Advaxis’ lead Lm Technology™
immunotherapies axalimogene filolisbac and ADXS-DUAL target
HPV-associated cancers and are in clinical trials for four
potential indications, including Phase 3 in invasive cervical
cancer and metastatic cervical cancer in combination with
nivolumab, Phase 2 in head and neck cancer, and Phase 2 in anal
cancer. The FDA has granted axalimogene filolisbac orphan drug
designation for each of these three clinical settings, as well as
Fast Track designation for adjuvant therapy for HRLACC patients and
a SPA for the Phase 3 AIM2CERV trial in HRLACC patients.
Axalimogene filolisbac has also been classified as an advanced
therapy medicinal product for the treatment of cervical cancer by
the EMA’s CAT. Advaxis has two additional immunotherapy products:
ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid
tumors, in human clinical development. In addition, Advaxis and
Amgen are developing ADXS-NEO, an investigational cancer
immunotherapy treatment designed to activate a patient's immune
system to respond against the unique mutations, or neoepitopes,
contained in and identified from each individual patient's tumor,
with plans to enter the clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop the next generation of cancer immunotherapies,
and the safety and efficacy of Advaxis’ proprietary
immunotherapies, axalimogene filolisbac and ADXS-DUAL. These
forward-looking statements are subject to a number of risks
including the risk factors set forth from time to time in Advaxis’
SEC filings including, but not limited to, its report on Form 10-K
for the fiscal year ended October 31, 2016, which is available at
http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170609005110/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
Affairsheber@advaxis.comorMedia Contact:JPA Health
CommunicationsDavid Connolly, 617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024